Palatin Technologies (@palatintech) 's Twitter Profile
Palatin Technologies

@palatintech

We discover and develop novel therapeutics for patients living with inflammatory and autoimmune conditions. $PTN

ID: 1202220380

linkhttps://www.palatin.com/ calendar_today20-02-2013 21:37:10

138 Tweet

810 Followers

120 Following

Palatin Technologies (@palatintech) 's Twitter Profile Photo

$PTN Vyleesi® (bremelanotide injection) delivers its 7th consecutive quarter of double-digit growth in product revenue and prescriptions dispensed. Prescriptions grew 18% & net product revenue increased 14% over the prior quarter.  bit.ly/3ScqRe9

$PTN Vyleesi® (bremelanotide injection) delivers its 7th consecutive quarter of double-digit growth in product revenue and prescriptions dispensed. Prescriptions grew 18% & net product revenue increased 14% over the prior quarter.  bit.ly/3ScqRe9
Palatin Technologies (@palatintech) 's Twitter Profile Photo

🔥 Breaking: Palatin Technologies $PTN reveals positive results from our Phase 3 trial of PL9643 for Dry Eye Disease at ASCRS 2024! 🌐 Quick relief & excellent safety. Dive into the future of eye care with us! 🚀 #EyeHealth #Biotech palatin.com/press_releases…

🔥 Breaking: Palatin Technologies $PTN reveals positive results from our Phase 3 trial of PL9643 for Dry Eye Disease at ASCRS 2024! 🌐 Quick relief & excellent safety. Dive into the future of eye care with us! 🚀 #EyeHealth #Biotech palatin.com/press_releases…
Palatin Technologies (@palatintech) 's Twitter Profile Photo

Palatin Announces 1-for-50 Reverse Stock Split Read the Full Press Release 👉 palatin.com/press_releases… #PTN #PTNT #NYSE #OTCQB #News

Palatin Announces 1-for-50 Reverse Stock Split 

Read the Full Press Release 👉 palatin.com/press_releases…

#PTN #PTNT #NYSE #OTCQB #News
Palatin Technologies (@palatintech) 's Twitter Profile Photo

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases Read the Full Press Release 👉 palatin.com/press_releases… #PTN #PTNT #NYSE #OTCQB #News

Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases 

Read the Full Press Release 👉 palatin.com/press_releases…

#PTN #PTNT #NYSE #OTCQB #News
Palatin Technologies (@palatintech) 's Twitter Profile Photo

Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim Read the Full Press Release 👉 palatin.com/press_releases… #PTN #PTNT #NYSE #OTCQB #News

Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim 

Read the Full Press Release 👉 palatin.com/press_releases…

#PTN #PTNT #NYSE #OTCQB #News
Palatin Technologies (@palatintech) 's Twitter Profile Photo

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering Read the Full Press Release 👉 palatin.com/press_releases… #PTN #PTNT #NYSE #OTCQB #News

Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering 

Read the Full Press Release 👉 palatin.com/press_releases…

#PTN #PTNT #NYSE #OTCQB #News
Palatin Technologies (@palatintech) 's Twitter Profile Photo

Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity Read the Full Press Release 👉 palatin.com/press_releases… #PTN #PTNT #NYSE #OTCQB #News

Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity 

Read the Full Press Release 👉 palatin.com/press_releases…

#PTN #PTNT #NYSE #OTCQB #News
Palatin Technologies (@palatintech) 's Twitter Profile Photo

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters’ Over-Allotment Option Read the Full Press Release 👉 palatin.com/press_releases… #PTN #PTNT #NYSE #OTCQB #News

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters’ Over-Allotment Option 

Read the Full Press Release 👉 palatin.com/press_releases…

#PTN #PTNT #NYSE #OTCQB #News
Palatin Technologies (@palatintech) 's Twitter Profile Photo

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Read the Full Press Release 👉 palatin.com/press_releases… #PTN #PTNT #NYSE #OTCQB #News

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update 

Read the Full Press Release 👉 palatin.com/press_releases…

#PTN #PTNT #NYSE #OTCQB #News
Palatin Technologies (@palatintech) 's Twitter Profile Photo

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Read the Full Press Release 👉 palatin.com/press_releases… #PTN #PTNT #NYSE #OTCQB #News

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update 

Read the Full Press Release 👉 palatin.com/press_releases…

#PTN #PTNT #NYSE #OTCQB #News